

Siemens Healthineers Shows Continued Positive Order Momentum, Confirms Outlook



Siemens Healthineers AG today announces its results for the third quarter of fiscal year 2024 ended June 30, 2024.

Q3 Fiscal Year 2024

- Good equipment book-to-bill ratio of 1.07 further increases already high order backlog
- Comparable revenue growth of 4.3% against a very strong prior-year quarter (10.1% excluding rapid COVID-19 antigen tests) and despite continued order delays in China
- Imaging comparable revenue growth of 3.8% against sharp growth in the prior-year quarter; adjusted EBIT margin of 20.0%
- Diagnostics comparable revenue growth of 2.1%; adjusted EBIT margin of 7.4% clearly above the prior-year quarter
- Varian comparable revenue growth of 9.6%; adjusted EBIT margin of 16.6% shows clear improvement over prior-year quarter
- Advanced Therapies comparable revenue growth of 0.4% against significant growth in the prior-year quarter; adjusted EBIT margin of 13.9%
- Overall adjusted EBIT margin of 15.2%
- Adjusted basic earnings per share of €0.52

Outlook for Fiscal Year 2024

We confirm our expectation of comparable revenue growth of between 4.5% and 6.5% (between 5.0% and 7.0% excluding revenue from rapid COVID-19 antigen tests) and adjusted basic earnings per share of between €2.10 and €2.30.

Bernd Montag, CEO of Siemens Healthineers AG:

We made good progress again in the third quarter, despite ongoing order delays in China. Varian and Diagnostics especially contributed to the strong operating performance. We confirm our outlook for the financial year.

Source & Image Credit: [Siemens Healthineers](#)

Published on : Wed, 31 Jul 2024